Adiponectin has anti-diabetic and anti-atherogenic effects, and when decreased, it promotes the risk of developing metabolic disorders such as insulin resistance and cardiovascular diseases (CVDs) in patients with opium use disorder. The gene discussed is ADIPOQ; the disease is Insulin resistance.